Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Aránzazu Sancho-López"'
Autor:
Antonio Gómez-Outes, Aránzazu Sancho-López, Antonio J. Carcas Sansuan, Cristina Avendaño-Solá
Publikováno v:
Pharmacological Research, Vol 199, Iss , Pp 107045- (2024)
Since the 1980s, medical specialists in Clinical Pharmacology have been playing a crucial role in the development of drug regulation in Spain. In this article we report on the activities carried out and the prospects for development in three very rel
Externí odkaz:
https://doaj.org/article/d0eb1a89545e4821b467ff6ca22fdfbd
Autor:
Elena Diago-Sempere, José Luis Bueno, Aránzazu Sancho-López, Elena Múñez Rubio, Ferrán Torres, Rosa Malo de Molina, Ana Fernández-Cruz, Isabel Salcedo de Diego, Ana Velasco-Iglesias, Concepción Payares-Herrera, Inmaculada Casas Flecha, Cristina Avendaño-Solà, Rafael Duarte Palomino, Antonio Ramos-Martínez, Belén Ruiz-Antorán
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-14 (2021)
Abstract Background COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with p
Externí odkaz:
https://doaj.org/article/6132297c8d1646ecbb0de369893edf99
Autor:
Javier García‐Pérez, Mercedes Bermejo, Almudena Ramírez‐García, Humberto Erick De La Torre‐Tarazona, Almudena Cascajero, María Castillo de la Osa, Paloma Jiménez, Marta Aparicio Gómez, Esther Calonge, Aránzazu Sancho‐López, Concepción Payares‐Herrera, Rocio Layunta Acero, Laura Vicente‐Izquierdo, Cristina Avendaño‐Solá, José Alcamí, Mayte Pérez‐Olmeda, Francisco Díez‐Fuertes
The humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern elicited by vaccination was evaluated in COVID-19 recovered individuals (Rec) separated 1-3 months (Rec2m) or 4-12 months (Rec9m) pos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::946e28deab2b434c7e9de3b75826959e
https://hdl.handle.net/20.500.12105/16083
https://hdl.handle.net/20.500.12105/16083
Autor:
Aránzazu Sancho-López, Doris Hovgaard, Sílvia Duarte, Sinan B. Sarac, Marcia Sofia Sanches de Castro Lopes Silva, Lucia López Anglada Fernández, Concepción Payares-Herrera, Sotirios Michaleas, Harald Enzmann, Isabel Garcia, Francesco Pignatti, Victor Mangas-Sanjuan, Anne Marie Dalseg, Elisabeth Penninga, Carolina Prieto Fernández, Jorge Camarero Jimenez, Aldana Rosso
Publikováno v:
Oncologist
The use of daratumumab in combination with established regimens for the treatment of newly diagnosed multiple myeloma has recently been authorized by the European Medicines Agency based on results from three separate phase III randomized, active cont
Autor:
David, García-Azorín, Edurne, Lázaro, David, Ezpeleta, Ramón, Lecumberri, Rafael de la, Cámara, Mar, Castellanos, Cristina Iñiguez, Martínez, Lara, Quiroga-González, Gabriela Elizondo, Rivas, Aránzazu, Sancho-López, Pilar Rayón, Iglesias, Eva, Segovia, Consuelo, Mejías, Dolores Montero, Corominas
Publikováno v:
Neurologia (Barcelona, Spain).
We describe the epidemiological and clinical characteristics of thrombosis with thrombocytopenia syndrome (TTS) cases reported in Spain.We included all venous or arterial thrombosis with thrombocytopenia following adenovirus vector-based vaccines (As
Autor:
Víctor Moreno-Torres, Enrique Sánchez-Chica, Raquel Castejón, Antonio-Francisco Caballero Bermejo, Patricia Mills, Elena Diago-Sempere, Silvia Rosado, Aránzazu Sancho-López, Juan-Antonio Vargas-Núñez, Belén Ruiz-Antorán, Ana Fernández-Cruz
Publikováno v:
Annals of palliative medicine. 11(8)
Red blood cell distribution width (RDW) could reflect interleukin-6 (IL-6) systemic activity since anisocytosis represents the inhibition of erythropoiesis, leaded by the hyperinflammatory background. Our objective was to analyze RDW performance to p
Autor:
Aránzazu, Sancho-López, Antonio F, Caballero-Bermejo, Belén, Ruiz-Antorán, Elena, Múñez Rubio, Mercedes, García Gasalla, Juan, Buades, Marta, González Rozas, María, López Veloso, Ana, Muñoz Gómez, Ana, Cuenca Abarca, Pedro, Durán Del Campo, Fátima, Ibáñez, Alberto, Díaz de Santiago, Yolanda, Romero, Jorge, Calderón, Ilduara, Pintos, Adrián, Ferre Beltrán, Gustavo, Centeno Soto, José, Campos, Antonio, Ramos Martínez, Cristina, Avendaño-Solá, Ana, Fernández Cruz, Fuencisla Gómez, Ruiz
Publikováno v:
Infectious Diseases and Therapy
Introduction SARS-CoV-2 pneumonia is often associated with hyper-inflammation. The cytokine-storm-like is one of the targets of current therapies for coronavirus disease 2019 (COVID-19). High Interleukin-6 (IL6) blood levels have been identified in s
Autor:
Pilar Garrido, Rafael de la Cámara, Marti de Gracia M, Rovira A, D. Ezpeleta, Martínez Ci, Margüello Er, David García-Azorín, Cristina Avendaño-Solá, Ramón Lecumberri, Mar Castellanos, Aránzazu Sancho-López
Publikováno v:
Neurologia (Barcelona, Spain)
Introducción: Se han reportado casos de trombosis venosas cerebrales en personas vacunadas frente a COVID-19 con vacunas vectoriazadas con adenovirus no replicantes. Aportamos recomendaciones sobre el diagnóstico y manejo de pacientes con esta comp
Autor:
Aránzazu Sancho-López, Antonio Ramos-Martínez, Ferran Torres, Rosa Malo de Molina, Concepción Payares-Herrera, Cristina Avendaño-Solá, Belén Ruiz-Antorán, Elena Múñez Rubio, Ana Fernández-Cruz, Rafael Duarte Palomino, José Luis Bueno, Inmaculada Casas Flecha, Elena Diago-Sempere, Ana Velasco-Iglesias, Isabel Salcedo de Diego
Publikováno v:
Repisalud
Instituto de Salud Carlos III (ISCIII)
Trials
Trials, Vol 22, Iss 1, Pp 1-14 (2021)
Instituto de Salud Carlos III (ISCIII)
Trials
Trials, Vol 22, Iss 1, Pp 1-14 (2021)
BackgroundCOVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with proven effi
Autor:
María J. Pedrosa-Martínez, Paloma Gijón, Víctor Moreno-Torres, Consuelo Pedrós, Ferran Torres, Aránzazu Sancho-López, Ana Fernández-Cruz, Francisco Abad-Santos, Enrique Sánchez-Chica, Itziar de Pablo-López, Paulina García-López, Consuelo Rodríguez-Jiménez, Guillermo Prada-Ramallal, Rocío Sanjuan-Jimenez, Ana Aldea-Perona, Carolina Hernández-Carballo, Belén Ruiz-Antorán, Ruth M. Aparicio-Hernández, Lourdes Cabrera-García, E. Montané, Roser Llop-Rius, Josefa A. Aguilar-García, Clara M. Rosso-Fernández, Evelyn I. Ortiz-Barraza
Publikováno v:
Infectious Diseases and Therapy
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
BackgroundWe aimed to determine the impact of tocilizumab use in severe COVID-19 pneumonia mortality.MethodsWe performed a multicentre retrospective cohort study in 18 tertiary hospitals in Spain, from March to April 2020. Consecutive patients admitt